Dermira, Inc. (NASDAQ:DERM)’s share price traded up 0.1% during trading on Friday . The company traded as high as $25.90 and last traded at $25.45. 103,995 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 427,988 shares. The stock had previously closed at $25.43.

A number of equities analysts have recently commented on the company. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Cantor Fitzgerald assumed coverage on Dermira in a research note on Thursday, June 22nd. They issued an “overweight” rating and a $45.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price objective on shares of Dermira in a research note on Tuesday, July 18th. Evercore ISI assumed coverage on Dermira in a research note on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price objective on the stock. Finally, Mizuho dropped their price objective on Dermira from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Four research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $44.40.

The firm’s market cap is $1.06 billion. The company has a 50-day moving average price of $24.98 and a 200-day moving average price of $29.89.

Dermira (NASDAQ:DERM) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by $0.04. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1 million. Equities research analysts predict that Dermira, Inc. will post ($4.20) EPS for the current fiscal year.

In related news, insider Eugene A. Bauer sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $30.01, for a total value of $75,025.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas G. Wiggans sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $29.06, for a total transaction of $145,300.00. The disclosure for this sale can be found here. Insiders sold a total of 11,700 shares of company stock valued at $337,537 over the last quarter. 13.30% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its position in Dermira by 15.6% during the second quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock worth $114,294,000 after acquiring an additional 529,405 shares during the last quarter. Jennison Associates LLC lifted its position in Dermira by 16.7% during the second quarter. Jennison Associates LLC now owns 2,632,994 shares of the biopharmaceutical company’s stock worth $76,725,000 after acquiring an additional 377,554 shares during the last quarter. TimesSquare Capital Management LLC lifted its position in Dermira by 6.8% during the first quarter. TimesSquare Capital Management LLC now owns 2,588,661 shares of the biopharmaceutical company’s stock worth $88,299,000 after acquiring an additional 164,950 shares during the last quarter. Vanguard Group Inc. lifted its position in Dermira by 9.8% during the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock worth $40,735,000 after acquiring an additional 125,157 shares during the last quarter. Finally, Voya Investment Management LLC lifted its position in Dermira by 61.4% during the second quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock worth $35,783,000 after acquiring an additional 467,356 shares during the last quarter. Hedge funds and other institutional investors own 97.56% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/10/dermira-inc-derm-trading-0-1-higher.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.